Status: Not yet recruiting
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus
This is a randomized, open-label, multi-center, active-controlled Phase 2 clinical trial to evaluate the efficacy and safety of switching from once-weekly dulaglutide to PG-102(MG12) in patients with type 2 diabetes mellitus receiving stable dulaglutide therapy. The treatment period is 32 weeks, with an additional 4-week safety follow-up. The primary endpoint is the change in HbA1c(%) from baseline at Week 32.
Participants needed: 60
Trial details
Phase: Phase 2Age: 19-75Biological sex: AllType: InterventionalSponsor: ProGen. Co., Ltd.Updated: Jul 1, 2026
Eligibility criteria
Adults aged 19 to 75 years who provide informed consent. [+5]
Received any investigational medicinal product within 30 days prior to screening... [+19]